NCT04003610 2025-11-04Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)Incyte CorporationPhase 2 Terminated7 enrolled 10 charts
NCT01625260 2024-07-19A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerAltor BioSciencePhase 1/2 Terminated12 enrolled 13 charts
NCT02887248 2023-12-05Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial CarcinomaSCRI Development Innovations, LLCPhase 2 Terminated3 enrolled 9 charts
NCT03737123 2023-09-13Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial CarcinomaHoosier Cancer Research NetworkPhase 2 Terminated6 enrolled 18 charts
NCT04039867 2023-08-21Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder CancerUniversity of California, IrvinePhase 2 Terminated17 enrolled 9 charts
NCT04060342 2022-08-18GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaGossamer Bio Inc.Phase 1 Terminated61 enrolled